The newly published report by IMARC Group, titled ”Familial Primary Pulmonary Hypertension Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033″, presents a comprehensive analysis of the familial primary pulmonary hypertension market. The report provides an overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent advancements in the seven major markets (7MM). The report also highlights key segments and market drivers, as well as challenges faced by industry players.
Request a Sample Report: https://www.imarcgroup.com/familial-primary-pulmonary-hypertension-market/requestsample
Familial Primary Pulmonary Hypertension Market Size:
The 7 major familial primary pulmonary hypertension markets are expected to exhibit a CAGR of 4.5% during 2023-2033.
What is familial primary pulmonary hypertension?
Familial primary pulmonary hypertension refers to a rare autosomal dominant condition characterized by specific changes in pulmonary arterioles, leading to increased pulmonary artery pressures, right ventricular failure, and eventual death. Some of the common symptoms associated with the condition include shortness of breath, fatigue, dizziness, chest pain, ankle, leg, and abdominal swelling, bluish lips and skin, and heart palpitations. Diagnosis involves assessing symptoms, medical history, and physical examination. An echocardiogram is used to visualize heart function. Genetic testing may be conducted to identify chromosomal irregularities and gene variations linked to the condition. Imaging techniques such as chest X-rays, computed tomography scans, and magnetic resonance imaging help evaluate chest abnormalities and exclude other health issues.
Ask an Analyst for Report Customization with Table of Contents: https://www.imarcgroup.com/familial-primary-pulmonary-hypertension-market
What are the key drivers and trends in the familial primary pulmonary hypertension market?
The familial primary pulmonary hypertension market is primarily driven by the increasing prevalence of mutations in the genetic material responsible for regulating cell growth and division in blood vessels. Additionally, the growing use of vasodilators such as calcium channel blockers, phosphodiesterase-5 inhibitors, and endothelin receptor antagonists to reduce high blood pressure in the pulmonary arteries and alleviate the workload on the heart muscle is contributing to a positive market outlook. Balloon atrial septostomy procedures are also widely adopted as they can ease strain on the right ventricle by decompressing the right atrium and improving heart balance, further boosting the market growth. Besides this, the rising popularity of recombinant fusion protein therapy, designed to target specific mechanisms or pathways associated with the disease for more effective and targeted treatment compared to traditional therapies, is expected to drive the familial primary pulmonary hypertension market in the forecast period.
What is included in the report segmentation?
The report covers the following aspects:
Report Period:
- Base Year: 2022
- Historical Period: 2017-2022
- Market Forecast: 2023-2033
Countries Included:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the familial primary pulmonary hypertension
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the familial primary pulmonary hypertension
- Reimbursement scenario in the market
- In-market and pipeline drugs
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Regulatory Status
Key Questions Answered in this Report:
- How has the familial primary pulmonary hypertension performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
- What was the country-wise size of the familial primary pulmonary hypertension across the seven major markets in 2022 and what will it look like in 2033?
- What is the growth rate of the familial primary pulmonary hypertension across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
How This Report Can Help You:
- The report on familial primary pulmonary hypertension presents a comprehensive overview and analysis of the epidemiology and market for this condition in the seven major markets (7MM): the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
- With insights into both current and emerging therapies in the 7MM, this report offers valuable information for businesses seeking to understand trends and opportunities within the familial primary pulmonary hypertension.
- The familial primary pulmonary hypertension report covers historical and forecasted market data, including epidemiology scenario, providing a reliable and informative resource for developing effective business strategies in 7MM.
- Our report on the familial primary pulmonary hypertension can help businesses stay abreast of the trends and drivers, gain a competitive edge and drive success.
About Us: –
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800